Literature DB >> 17384453

Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade.

Daizo Kawasaki1, Keisuke Kosugi, Hidehiko Waki, Kazuhiro Yamamoto, Takeshi Tsujino, Tohru Masuyama.   

Abstract

BACKGROUND: We attempted to test the hypothesis that chronic angiotensin II type 1A receptor blockade (ARB) alters myocardial collagen turnover leading to an improvement of diastolic dysfunction in diabetic patients. METHODS AND
RESULTS: Forty-eight type 2 diabetic patients were divided into 2 groups: 38 treated with candesartan for 6 months, and 10 without candesartan, as controls. Doppler mitral flow velocity pattern and biomarkers of collagen type I turnover were assessed before and after ARB during a 6-month period. The mitral E/A ratio increased from 0.65+/-0.11 to 0.75+/-0.19. The carboxy-terminal propeptide of procollagen type I (PIP), an index of collagen type I synthesis, decreased and the carboxy-terminal telopeptide of collagen type I (CITP), an index of collagen type I degradation, increased following ARB. Consequently, the PIP/CITP ratio, an index of coupling between the synthesis and degradation of collagen type I, decreased. None of the indexes changed in the control group. The change in left ventricular chamber stiffness did not correlate with the change in PICP (r=0.08, p=NS), but it did with the changes in CITP or in the PIP/CITP ratio (r=0.35, p<0.05; r=0.39, p<0.05).
CONCLUSIONS: Chronic ARB improves diastolic dysfunction in diabetic patients, at least partially through the attenuation of myocardial fibrosis, by regulating collagen turnover, particularly by facilitating collagen degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17384453     DOI: 10.1253/circj.71.524

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  20 in total

1.  Impact of surgical ventricular reconstruction for ischemic dilated cardiomyopathy on restrictive filling pattern.

Authors:  Yasuhiro Shudo; Goro Matsumiya; Taichi Sakaguchi; Shigeru Miyagawa; Takashi Yamauchi; Koji Takeda; Shunsuke Saito; Kazuhiro Taniguchi; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-08-12

Review 2.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

3.  Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach.

Authors:  Falah Aboukhoudir; Sofiene Rekik
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-18       Impact factor: 2.357

Review 4.  Diabetic cardiomyopathy: signaling defects and therapeutic approaches.

Authors:  Joseph S Dobrin; Djamel Lebeche
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-03

5.  Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.

Authors:  Rie Futai; Takahide Ito; Yasunori Kawanishi; Fumio Terasaki; Yasushi Kitaura
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

6.  Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.

Authors:  Jewell A Jessup; Brian M Westwood; Mark C Chappell; Leanne Groban
Journal:  Ther Adv Cardiovasc Dis       Date:  2009-06-16

Review 7.  Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy.

Authors:  Brahmanaidu Parim; V V Sathibabu Uddandrao; Ganapathy Saravanan
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

8.  Diabetic cardiomyopathy: is resistin a culprit?

Authors:  Djamel Lebeche
Journal:  Cardiovasc Diagn Ther       Date:  2015-10

Review 9.  The failing diabetic heart: focus on diastolic left ventricular dysfunction.

Authors:  Loek van Heerebeek; Aernout Somsen; Walter J Paulus
Journal:  Curr Diab Rep       Date:  2009-02       Impact factor: 4.810

10.  3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats.

Authors:  Fay Lin Khong; Yuan Zhang; Amanda J Edgley; Weier Qi; Kim A Connelly; Owen L Woodman; Henry Krum; Darren J Kelly
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.